REGN250110P745000
- 9.36
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Truist Financial Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,004
Regeneron Pharmaceuticals Analyst Ratings
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,184
RBC Trims Price Target on Regeneron Pharmaceuticals to $1,184 From $1,215, Keeps Outperform Rating
Bernstein Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,070
CCORF Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,152
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $950 From $1,190, Keeps Outperform Rating
Leerink Partners Keeps Their Hold Rating on Regeneron (REGN)
Regeneron Pharma Price Target Announced at $165.00/Share by Canaccord Genuity
Regeneron Pharma Initiated at Hold by Canaccord Genuity
Regeneron Pharmaceuticals Analyst Ratings
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,195
Regeneron Pharmaceuticals Analyst Ratings
B of A Securities Reinstates Underperform on Regeneron Pharmaceuticals, Announces $565 Price Target
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,186
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,186
Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $1,186 From $1,184, Maintains Overweight Rating
RBC Capital Remains a Buy on Regeneron (REGN)